Detailed view for LmjF.35.4990

Basic information

TDR Targets ID: 27649
Leishmania major, phosphatidylcholine:ceramide cholinephosphotransferase 2
Source Database / ID:  TriTrypDB  GeneDB

pI: 6.6292 | Length (AA): 338 | MW (Da): 37644 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 6

Druggability Group : DG2

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF14360   PAP2 superfamily C-terminal

Gene Ontology

Mouse over links to read term descriptions.
No GO information for this protein.

Metabolic Pathways

Sphingolipid metabolism (KEGG)
Global map (KEGG)

Structural information

Modbase 3D models:

There is 1 model calculated for this protein. More info on this model, including the model itself is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
113 210 4oh3 (A) 52 163 31.00 0.25 0.47 0.448041 0.11

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Upper 80-100% percentile metacyclic. Fernandes MC
Upregulation Percent Ranking Stage Dataset
Upper 60-80% percentile amastigotes. Fernandes MC
Show/Hide expression data references
  • Fernandes MC Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures.

Orthologs

Ortholog group members (OG5_139061)

Species Accession Gene Product
Leishmania braziliensis LbrM.34.4930   inositol phosphorylceramide synthase
Leishmania donovani LdBPK_355030.1   sphingomyelin/ceramide phosphorylethanolamine synthase, bifunctional
Leishmania infantum LinJ.35.5030   inositol phosphorylceramide synthase
Leishmania major LmjF.35.4990   phosphatidylcholine:ceramide cholinephosphotransferase 2
Leishmania mexicana LmxM.34.4990   hypothetical protein, conserved
Trypanosoma brucei gambiense Tbg972.9.5300   phosphatidylcholine:ceramide cholinephosphotransferase 2, putative
Trypanosoma brucei gambiense Tbg972.9.5330   phosphatidylcholine:ceramide cholinephosphotransferase 2, putative
Trypanosoma brucei gambiense Tbg972.9.5350   phosphatidylcholine:ceramide cholinephosphotransferase 2, putative
Trypanosoma brucei gambiense Tbg972.9.5340   phosphatidylcholine:ceramide cholinephosphotransferase 2, putative
Trypanosoma brucei Tb927.9.9380   sphingomyelin/ceramide phosphorylethanolamine synthase, bifunctional
Trypanosoma brucei Tb927.9.9390   sphingomyelin/ceramide phosphorylethanolamine synthase, bifunctional
Trypanosoma congolense TcIL3000_0_23730   sphingomyelin/ceramide phosphorylethanolamine synthase, bifunctional
Trypanosoma cruzi TcCLB.510729.290   sphingomyelin/ceramide phosphorylethanolamine synthase, bifunctional
Trypanosoma cruzi TcCLB.506885.124   sphingomyelin/ceramide phosphorylethanolamine synthase, bifunctional

Essentiality

LmjF.35.4990 has one or more orthologs with essentiality data
Gene/Ortholog Organism Phenotype Source Study
Tb09.211.1000 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (3 days) alsford
Tb09.211.1000 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (6 days) alsford
Tb09.211.1000 Trypanosoma brucei no significant loss or gain of fitness in procyclic forms alsford
Tb09.211.1000 Trypanosoma brucei significant gain of fitness in differentiation of procyclic to bloodstream forms alsford
Tb09.211.1010 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (3 days) alsford
Tb09.211.1010 Trypanosoma brucei significant loss of fitness in bloodstream forms (6 days) alsford
Tb09.211.1010 Trypanosoma brucei no significant loss or gain of fitness in procyclic forms alsford
Tb09.211.1010 Trypanosoma brucei no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms alsford
Show/Hide essentiality data references
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database
  • wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Species Known druggable target Linked compounds Reference
Trypanosoma cruzi sphingomyelin/ceramide phosphorylethanolamine synthase, bifunctional Compounds References
Trypanosoma cruzi sphingomyelin/ceramide phosphorylethanolamine synthase, bifunctional Compounds References
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model

Ranking Plot

Putative Drugs List

Compound Raw Global Species
0.0456 0.503 1
0.0181 0.4974 0.6886
0.0117 0.4835 1
0.0542 0.4903 1
0.0512 0.5043 1
0.0452 0.2515 1
0.046 0.4883 1
0.0541 0.4853 1
0.0516 0.4956 1
0.0529 0.4956 1
0.046 0.5051 1
0.0527 0.4853 1
0.052 0.4918 1
0.0547 0.4842 0.4746
0.0464 0.3654 1
0.0537 0.2515 1
0.0547 0.4842 0.4746
0.0549 0.5062 1
0.0449 0.5077 1
0.0549 0.4924 1
0.0533 0.4909 1
0.0452 0.2515 1
0.0467 0.5036 1
0.0557 0.4924 1
0.0511 0.4853 1
0.046 0.5051 1
0.0523 0.332 1
0.0467 0.5032 1
0.0467 0.5036 1
0.0459 0.4368 1
0.0451 0.2581 1
0.0549 0.4967 1
0.0447 0.5025 1
0.0454 0.2773 1
0.046 0.5011 1
0.0488 0.4888 1
0.0511 0.4853 1
0.0456 0.503 1
0.0477 0.4853 1
0.0467 0.488 1
0.0475 0.4744 1
0.0482 0.4662 1
0.0513 0.4852 1
0.0484 0.4853 1
0.046 0.5051 1
0.047 0.4807 1
0.0506 0.5054 1
0.0557 0.501 1
0.0459 0.4923 1
0.0488 0.4978 1
0.048 0.48 1
0.0541 0.4853 1
0.0489 0.4825 1
0.0181 0.4974 0.6886
0.0457 0.2663 1
0.048 0.5011 1
0.0508 0.4853 1
0.0511 0.4853 1
0.0456 0.503 1
0.0456 0.503 1
0.0477 0.4853 1
0.0549 0.4924 1
0.0457 0.3263 1
0.0452 0.4103 1
0.0445 0.3263 1
0.0446 0.4187 1
0.0477 0.4853 1
0.0557 0.4967 1
0.0506 0.5054 1
0.0445 0.3263 1
0.0549 0.4967 1
0.052 0.4918 1

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier LmjF.35.4990 (Leishmania major), phosphatidylcholine:ceramide cholinephosphotransferase 2
Title for this comment
Comment